{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T22:46:33Z","timestamp":1794264393610,"version":"4.9.0"},"reference-count":98,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":80,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalofnuclearcardiology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.nuclcard.2026.102724","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T12:03:42Z","timestamp":1778846622000},"page":"102724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"S","title":["Quantitative cardiac amyloid radionuclide imaging"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4676-2433","authenticated-orcid":false,"given":"Robert JH.","family":"Miller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier F.","family":"Clerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-2151","authenticated-orcid":false,"given":"Sarah AM.","family":"Cuddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-5651","authenticated-orcid":false,"given":"Benjamin","family":"Auer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Foley","family":"Kijewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward J.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr J.","family":"Slomka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-1185","authenticated-orcid":false,"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nuclcard.2026.102724_bib1","first-page":"322","article-title":"Canadian Cardiovascular Society\/Canadian Heart Failure Society joint position statement on the evaluation and management of patients with cardiac amyloidosis","volume":"36","author":"Fine","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib2","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2026.102724_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.jcmg.2024.10.011","article-title":"The last decade in cardiac amyloidosis: advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response","volume":"18","author":"Fontana","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib4","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib5","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1007\/s12350-022-03059-5","article-title":"Radiopharmaceutical supply disruptions and the use of (99m)Tc-hydroxymethylene diphosphonate as an alternative to (99m)Tc-pyrophosphate for the diagnosis of transthyretin cardiac amyloidosis: an ASNC Information Statement","volume":"29","author":"Miller","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib6","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.nuclcard.2026.102724_bib7","article-title":"A tale of two tracers - amyloid imaging with investigational radiotracers iodine ((124)I) evuzamitide and (99m)Tc-p5+14 (AT-05)","author":"Martin","year":"2025","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib8","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","article-title":"Cardiac amyloid detection by PET\/CT imaging of iodine ((124)I) evuzamitide ((124)I-p5+14): a phase 1\/2 study","volume":"16","author":"Wall","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib10","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using (18)F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18F]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib12","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","article-title":"Diagnostic accuracy of [(11)C]PIB positron emission tomography for detection of cardiac amyloidosis","volume":"13","author":"Rosengren","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib13","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1007\/s12350-022-02985-8","article-title":"Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM","volume":"30","author":"Sperry","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib14","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2025.102275","article-title":"Prognostic value of (99m)technetium-pyrophosphate single-photon emission computed tomography visual grade in patients with transthyretin cardiac amyloidosis on stabilization therapy","volume":"51","author":"Romero Pabon","year":"2025","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/13506129.2024.2420809","article-title":"PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study","volume":"32","author":"Suhr","year":"2025","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2026.102724_bib19","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jcmg.2020.05.005","article-title":"Quantitative bone-avid tracer SPECT\/CT for cardiac amyloidosis: a crucial step forward","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib20","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2967\/jnumed.112.111476","article-title":"An evidence-based review of quantitative SPECT imaging and potential clinical applications","volume":"54","author":"Bailey","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.2967\/jnumed.118.220657","article-title":"Solid-state detector SPECT myocardial perfusion imaging","volume":"60","author":"Slomka","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib22","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1007\/s12350-023-03256-w","article-title":"Comparison of cardio-focal and chest reconstruction of technetium-99m pyrophosphate scintigraphy for diagnosis of transthyretin cardiac amyloidosis: a quality assurance study","volume":"30","author":"Akincioglu","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12350-019-01831-8","article-title":"99m)Technetium pyrophosphate scintigraphy with cadmium zinc telluride cameras is a highly sensitive and specific imaging modality to diagnose transthyretin cardiac amyloidosis","volume":"27","author":"Flaherty","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib24","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40658-024-00627-1","article-title":"Comparison of a 3D CZT and conventional SPECT\/CT system for quantitative Lu-177 SPECT imaging","volume":"11","author":"Nuttens","year":"2024","journal-title":"EJNMMI Phys"},{"key":"10.1016\/j.nuclcard.2026.102724_bib25","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-025-07612-5","article-title":"Critical review of partial volume correction methods in PET and SPECT imaging: benefits, pitfalls, challenges, and future outlook","volume":"53","author":"Azimi","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib26","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2022.01.036","article-title":"Cardiac microcalcifications in transthyretin (ATTR) amyloidosis","volume":"352","author":"Thelander","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s12350-019-01675-2","article-title":"Examining the sensitivity of 18F-NaF PET for the imaging of cardiac amyloidosis","volume":"28","author":"Martineau","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.101845","article-title":"Role of (18)F-sodium fluoride positron emission tomography in imaging atherosclerosis","volume":"35","author":"Kwiecinski","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","article-title":"Amyloid PET imaging in cardiac amyloidosis: a pilot study using (18)F-flutemetamol positron emission tomography","volume":"33","author":"Dietemann","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib30","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jcmg.2025.01.018","article-title":"Early detection of transthyretin cardiac amyloidosis using (124)I-Evuzamitide positron emission tomography\/computed tomography","volume":"18","author":"Smiley","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib31","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using (124)I-Evuzamitide ((124)I-P5+14) versus (18)F-Florbetapir: a pilot PET\/CT study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1007\/s12350-020-02353-4","article-title":"Inter-observer reproducibility and intra-observer repeatability in (99m)Tc-pyrophosphate scan interpretation for diagnosis of transthyretin cardiac amyloidosis","volume":"29","author":"Singh","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib33","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1007\/s12350-020-02139-8","article-title":"Technetium pyrophosphate nuclear scintigraphy for cardiac amyloidosis: imaging at 1 vs 3 hours and planar vs SPECT\/CT","volume":"27","author":"Sperry","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib34","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.125.018745","article-title":"Diagnostic performance and interpreter experience of 1-Hour versus 3-Hour (99m)Tc-HMDP cardiac amyloid radionuclide imaging: a prospective, blinded comparison","volume":"19","author":"Tersalvi","year":"2026","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2025.102587","article-title":"Comparative performance of (99m)Tc-pyrophosphate vs. (99m)Tc-hydroxymethylene diphosphonate for cardiac amyloid radionuclide imaging","volume":"56","author":"Tersalvi","year":"2026","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib36","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD quantification in cardiac amyloidosis: a novel imaging biomarker","volume":"13","author":"Scully","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib37","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","article-title":"Cardiac amyloid imaging with 18F-Florbetaben PET: a pilot study","volume":"57","author":"Law","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib38","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s12350-022-03180-5","article-title":"Diagnostic value of heart-to-mediastinum ratio in (99m)Tc-pyrophospate SPECT\/CT for transthyretin cardiac amyloidosis","volume":"30","author":"Ikoma","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib39","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s12350-022-03133-y","article-title":"(99m)Tc-PYP SPECT and SPECT\/CT quantitation for diagnosing cardiac transthyretin amyloidosis","volume":"30","author":"Nichols","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.sult.2010.10.001","article-title":"Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy","volume":"31","author":"Kinahan","year":"2010","journal-title":"Semin Ultrasound CT MR"},{"key":"10.1016\/j.nuclcard.2026.102724_bib41","first-page":"283","article-title":"Dynamic acquisition of [(99m)Tc]Tc-Pyrophosphate SPECT\/CT images in transthyretin cardiac amyloidosis: a pilot study","volume":"67","author":"Auer","year":"2026","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib42","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute quantitation of cardiac (99m)Tc-Pyrophosphate using cadmium-zinc-telluride-based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib43","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1007\/s12350-021-02563-4","article-title":"Diagnostic and prognostic value of Technetium-99m pyrophosphate uptake quantitation for transthyretin cardiac amyloidosis","volume":"28","author":"Miller","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.jcmg.2024.05.002","article-title":"Prognostic value of left ventricular (18)F-Florbetapir uptake in systemic light-chain amyloidosis","volume":"17","author":"Clerc","year":"2024","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102019","article-title":"Quantitative (99m)Tc-pyrophosphate myocardial uptake: changes on transthyretin stabilization therapy","volume":"39","author":"Vijayakumar","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib46","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13550-021-00828-0","article-title":"Quantitative SPECT\/CT parameters of myocardial (99m)Technetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis","volume":"11","author":"Ben-Haim","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.nuclcard.2026.102724_bib47","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2967\/jnumed.124.267542","article-title":"Deep learning-enabled quantification of (99m)Tc-Pyrophosphate SPECT\/CT for cardiac amyloidosis","volume":"65","author":"Miller","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib48","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","volume":"24","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib49","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.2967\/jnumed.122.264866","article-title":"Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future","volume":"64","author":"Dorbala","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib50","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12350-018-1349-x","article-title":"Quantification of (11)C-PIB kinetics in cardiac amyloidosis","volume":"27","author":"Kero","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib51","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s12350-021-02608-8","article-title":"Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images","volume":"29","author":"Santarelli","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib52","article-title":"Parametric cardiac imaging with (18)F-Flutemetamol PET to evaluate the impact of tafamidis in patients with transthyretin cardiac amyloidosis","volume":"125","author":"Liu","year":"2026","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib53","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s00259-022-06028-9","article-title":"EANM practice guideline for quantitative SPECT-CT","volume":"50","author":"Dickson","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib54","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s12350-022-02988-5","article-title":"Quantitative single photon emission computed tomography derived standardized uptake values on 99mTc-PYP scan in patients with suspected ATTR cardiac amyloidosis","volume":"30","author":"Avalon","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib55","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1007\/s12350-023-03282-8","article-title":"Difference in cardiac uptake between 99mTc-HMDP and 99mTc-DPD for the non-invasive diagnosis of cardiac transthyretin amyloidosis","volume":"30","author":"Dietz","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2967\/jnumed.124.267869","article-title":"Nuclear cardiology surrogate biomarkers in clinical trials","volume":"66","author":"Miller","year":"2025","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2025.102273","article-title":"Test\u2013retest reproducibility of myocardial 99mTc-HMDP uptake quantification by SPECT-CT in suspected transthyretin cardiac amyloidosis","volume":"51","author":"Legallois","year":"2025","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib58","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s12350-019-01961-z","article-title":"Reproducibility and repeatability of assessment of myocardial light chain amyloidosis burden using (18)F-Florbetapir PET\/CT","volume":"28","author":"Nodoushani","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib59","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s12350-020-02274-2","article-title":"Quantitation of myocardial (99m)Tc-HMDP uptake with new SPECT\/CT cadmium zinc telluride (CZT) camera in patients with transthyretin-related cardiac amyloidosis: ready for clinical use?","volume":"29","author":"Bellevre","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2025.102199","article-title":"Validation of [99mTc]Tc-HMDP SPECT\/CT myocardium-to-blood ratio for the detection of ATTR cardiomyopathy","volume":"47","author":"Suomalainen","year":"2025","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2015.00023","article-title":"A routine PET\/CT protocol with simple calculations for assessing cardiac amyloid using 18F-Florbetapir","volume":"2","author":"Osborne","year":"2015","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib62","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","article-title":"(11)C-Pittsburgh B PET imaging in cardiac amyloidosis","volume":"8","author":"Lee","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib63","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","article-title":"Detection of cardiac amyloidosis with (18)F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy","volume":"46","author":"Kircher","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib64","first-page":"1","article-title":"Quantification of cardiac amyloid with [(18)F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis","author":"Mockelind","year":"2020","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2026.102724_bib65","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12350-020-02363-2","article-title":"(18)F-flutemetamol positron emission tomography in cardiac amyloidosis","volume":"29","author":"Papathanasiou","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2026.102707","article-title":"Assessment of cardiac involvement in rare forms of amyloidosis using PET\/CT with 124I-Evuzamitide (124I-p5+14, AT-01)","author":"Clerc","year":"2026","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib67","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease?","volume":"13","author":"Cuddy","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib68","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1093\/ehjci\/jead350","article-title":"Quantification of right ventricular amyloid burden with 18F-florbetapir PET\/CT and its association with right ventricular dysfunction and outcomes in light-chain amyloidosis","volume":"25","author":"Datar","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib69","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.693194","article-title":"Pilot study of F18-Florbetapir in the early evaluation of cardiac amyloidosis","volume":"8","author":"Sperry","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib70","article-title":"Kinetic analysis of cardiac dynamic (18)F-Florbetapir PET in healthy volunteers and amyloidosis patients: a pilot study","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.nuclcard.2026.102724_bib71","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.002954","article-title":"18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study","volume":"8","author":"Park","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"issue":"12","key":"10.1016\/j.nuclcard.2026.102724_bib72","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jchf.2024.07.007","article-title":"Functional status and quality of life in light-chain amyloidosis: advanced imaging, longitudinal changes, and outcomes","volume":"12","author":"Clerc","year":"2024","journal-title":"JACC Heart Failure"},{"key":"10.1016\/j.nuclcard.2026.102724_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101261","article-title":"DPD quantification correlates with extracellular volume and disease severity in wild-type transthyretin cardiac amyloidosis","volume":"3","author":"Rettl","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.nuclcard.2026.102724_bib74","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1007\/s12350-021-02806-4","article-title":"Quantitative technetium pyrophosphate and cardiovascular magnetic resonance in patients with suspected cardiac amyloidosis","volume":"29","author":"Roshankar","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib75","doi-asserted-by":"crossref","first-page":"944","DOI":"10.2967\/jnumed.123.266926","article-title":"Prognostic value of [(99m)Tc]Tc-DPD quantitative SPECT\/CT in patients with suspected and confirmed amyloid transthyretin-related cardiomyopathy and preserved left ventricular function","volume":"65","author":"Caobelli","year":"2024","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/ehjci\/jeae295","article-title":"Prognostic implication of DPD quantification in transthyretin cardiac amyloidosis","volume":"26","author":"Rettl","year":"2025","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib77","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","article-title":"Pittsburgh B compound positron emission tomography in patients with AL cardiac amyloidosis","volume":"75","author":"Lee","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib78","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib79","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib80","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.nuclcard.2026.102724_bib81","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter study of planar technetium 99m pyrophosphate cardiac imaging: predicting survival for patients with ATTR cardiac amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102075","article-title":"Assessing the effectiveness of tafamidis therapy in patients with transthyretin cardiac amyloidosis using 99mtechnetium pyrophosphate cardiac imaging","volume":"44","author":"Tasaka","year":"2025","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib83","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jaccas.2020.11.036","article-title":"First Follow-Up of cardiac amyloidosis treated by tafamidis, evaluated by absolute quantification in bone scintigraphy","volume":"3","author":"Bellevre","year":"2021","journal-title":"JACC Case Rep"},{"key":"10.1016\/j.nuclcard.2026.102724_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102056","article-title":"Single-photon emission computed tomography\/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis","volume":"42","author":"Godoy-Rivas","year":"2024","journal-title":"J Nucl Cardiol"},{"issue":"2","key":"10.1016\/j.nuclcard.2026.102724_bib85","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.nuclcard.2026.102724_bib86","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030512","article-title":"Use of Technetium-99m-Pyrophosphate single-photon emission computed tomography\/computed tomography in monitoring therapeutic changes of eplontersen in patients with hereditary transthyretin amyloid cardiomyopathy","volume":"13","author":"Yu","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.nuclcard.2026.102724_bib87","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1007\/s00259-025-07673-6","article-title":"Impact of disease-modifying therapy on [(99m)Tc]Tc-DPD SPECT\/CT markers in transthyretin cardiac amyloidosis enabled by artificial intelligence","volume":"53","author":"Spielvogel","year":"2026","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2025.102573","article-title":"Artificial intelligence-driven longitudinal quantification of technetium pyrophosphate uptake in cardiac amyloidosis: correlation with multimodality imaging and outcomes","volume":"56","author":"Miller","year":"2026","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.102077","article-title":"What do changes in myocardial bone-avid radiotracer uptake mean in transthyretin cardiac amyloidosis?","volume":"42","author":"Clerc","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib90","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/13506129.2018.1552852","article-title":"A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement","volume":"25","author":"Manwani","year":"2018","journal-title":"Amyloid"},{"key":"10.1016\/j.nuclcard.2026.102724_bib91","first-page":"1","article-title":"Longitudinal PET\/CT imaging with iodine ((124)I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis","author":"Lands","year":"2023","journal-title":"Amyloid"},{"issue":"12","key":"10.1016\/j.nuclcard.2026.102724_bib92","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jcmg.2025.07.017","article-title":"Changes in myocardial light chain amyloid burden after plasma cell therapy","volume":"18","author":"Benz","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.nuclcard.2026.102724_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.101809","article-title":"Deep learning approach for automated segmentation of myocardium using bone scintigraphy single-photon emission computed tomography\/computed tomography in patients with suspected cardiac amyloidosis","volume":"33","author":"Bhattaru","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.101942","article-title":"Fully automated quantitation of 99mTc-PYP SPECT\/CT images using artificial intelligence-based segmentation of low-dose CTAC","volume":"38","author":"Auer","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1016\/j.nuclcard.2026.102724_bib95","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41746-025-01526-0","article-title":"Holistic AI analysis of hybrid cardiac perfusion images for mortality prediction","volume":"8","author":"Marcinkiewicz","year":"2025","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.nuclcard.2026.102724_bib96","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad655.236","article-title":"Longitudinal evaluation of cardiac and extracardiac amyloid load in patients with AL and ATTR amyloidosis, measured by 124I-AT-01 PET\/CT imaging","volume":"44","author":"Martin","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.nuclcard.2026.102724_bib97","article-title":"CTLESS: a scatter-window projection and deep learning-based transmission-less attenuation compensation method for myocardial perfusion SPECT","author":"Yu","year":"2024","journal-title":"IEEE Trans Med Imag"},{"key":"10.1016\/j.nuclcard.2026.102724_bib98","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s12350-021-02672-0","article-title":"CT-free attenuation correction for dedicated cardiac SPECT using a 3D dual squeeze-and-excitation residual dense network","volume":"29","author":"Chen","year":"2022","journal-title":"J Nucl Cardiol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358126001054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358126001054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T06:42:03Z","timestamp":1784702523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358126001054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":98,"alternative-id":["S1071358126001054"],"URL":"https:\/\/doi.org\/10.1016\/j.nuclcard.2026.102724","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantitative cardiac amyloid radionuclide imaging","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nuclcard.2026.102724","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society of Nuclear Cardiology.","name":"copyright","label":"Copyright"}],"article-number":"102724"}}